{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:05:36Z","timestamp":1781499936533,"version":"3.54.1"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T00:00:00Z","timestamp":1454457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health"},{"name":"Maudsley NHS Foundation Trust and King's College London"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Take\u2010home naloxone is increasingly provided to prevent heroin overdose deaths. Naloxone 0.4\u20132.0\u00a0mg is licensed for use by injection. Some clinicians supply improvised nasal naloxone kits (outside lisenced approval). Is this acceptable?<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>(1) To consider provision of improvised nasal naloxone in clinical practice and (2) to search for evidence for pharmacokinetics and effectiveness (versus injection).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>(1) To document existing nasal naloxone schemes and published evidence of pharmacokinetics (systematic search of the CINAHL, Cochrane, <jats:styled-content style=\"fixed-case\">EMBASE<\/jats:styled-content> and MEDLINE databases and 18 records included in narrative synthesis). (2) To analyse ongoing studies investigating nasal naloxone (WHO International Clinical Trials Registry Platform and US NIH RePORT databases).<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>(1) Multiple studies report overdose reversals following administration of improvised intranasal naloxone. (2) Overdose reversal after nasal naloxone is frequent but may not always occur. (3) Until late 2015, the only commercially available naloxone concentrations were 0.4\u00a0mg\/ml and 2\u00a0mg\/2\u00a0ml. Nasal medications are typically 0.05\u20130.25\u00a0ml of fluid per nostril. The only published study of pharmacokinetics and bioavailability finds that nasal naloxone has poor bioavailability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Questions for debate<\/jats:title><jats:p>(1) Why are pharmacokinetics and bioavailability data for nasal naloxone not available before incorporation into standard clinical practice? (2) Does nasal naloxone have the potential to become a reliable clinical formulation? (3) What pre\u2010clinical and clinical studies should precede utilization of novel naloxone formulations as standard emergency medications?<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The addictions treatment field has rushed prematurely into the use of improvised nasal naloxone kits. Evidence of adequate bioavailability and acceptable pharmacokinetic curves are vital preliminary steps, especially when effective approved formulations exist.<\/jats:p><\/jats:sec>","DOI":"10.1111\/add.13209","type":"journal-article","created":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T17:03:58Z","timestamp":1454519038000},"page":"574-582","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?"],"prefix":"10.1111","volume":"111","author":[{"given":"John","family":"Strang","sequence":"first","affiliation":[{"name":"National Addiction Centre Institute of Psychiatry, Psychology and Neuroscience, King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"McDonald","sequence":"additional","affiliation":[{"name":"National Addiction Centre Institute of Psychiatry, Psychology and Neuroscience, King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basak","family":"Tas","sequence":"additional","affiliation":[{"name":"National Addiction Centre Institute of Psychiatry, Psychology and Neuroscience, King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Day","sequence":"additional","affiliation":[{"name":"National Addiction Centre Institute of Psychiatry, Psychology and Neuroscience, King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7338.678"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7291.895"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1999.9421993.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2008.146647"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g6580"},{"key":"e_1_2_8_7_1","unstructured":"United Nations Office on Drugs and Crime\/World Health Organization (UNODC\/WHO).Opioid overdose: preventing and reducing opioid overdose mortality.Vienna: United Nations.2013. Available at:http:\/\/www.unodc.org\/docs\/treatment\/overdose.pdf(accesssed 30 May 2014)."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000034"},{"key":"e_1_2_8_9_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).Preventing fatal overdoses: a systematic review of the effectiveness of take\u2010home naloxone.2015. Available at:http:\/\/www.emcdda.europa.eu\/publications\/emcdda\u2010papers\/naloxone\u2010effectiveness(accessed 1June2015)."},{"key":"e_1_2_8_10_1","unstructured":"World Health Organization (WHO).Community management of opioid overdose.2014. Available at:http:\/\/apps.who.int\/iris\/bitstream\/10665\/137462\/1\/9789241548816_eng.pdf?ua=1&ua=1(accessed 11November2014)."},{"key":"e_1_2_8_11_1","unstructured":"Fda.gov. FDA moves quickly to approve easy\u2010to\u2010use nasal spray to treat opioid overdose.2015. Available at:http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm473505.htm."},{"key":"e_1_2_8_12_1","volume-title":"Intranasal naloxone being introduced in Highland","author":"Greig E.","year":"2012"},{"key":"e_1_2_8_13_1","unstructured":"Centers for Disease Control (CDC).Opioid overdose prevention programs providing naloxone to laypersons\u2013\u2014United States 2014.2015. Available at:http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6423a2.htm(accessed 20June2015)."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2005.03.007"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2007.02097.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10903120290938797"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10903120600885134"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181816214"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2013.825691"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2005.tb06550.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02724.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/emj.19.4.375"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(92)90014-F"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/10826089409047912"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2008.12.009"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/10903120903144866"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2014.42584"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/10903127.2011.640763"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/10903127.2014.896961"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f174"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2012.07.004"},{"key":"e_1_2_8_32_1","volume-title":"Nasal naloxone, as take\u2010home provision for users and relatives in Norway: first experiences 2014 [cited","author":"Clausen T.","year":"2015"},{"key":"e_1_2_8_33_1","volume-title":"EMCDDA Insights: Preventing Overdose Deaths From Heroin and Other Opioids: Pre\u2010Provision of Emergency Naloxone (Take\u2010Home Naloxone)","author":"Strang J."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(90)90136-3"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(87)90147-5"},{"key":"e_1_2_8_36_1","unstructured":"Medicines and Healthcare Products Regulatory Agency (MHRA).Buccal midazolam (Buccolam): new authorised medicine for paediatric use\u2014care needed when transferring from unlicensed formulations.2011. Available at:http:\/\/www.mhra.gov.uk\/Safetyinformation\/DrugSafetyUpdate\/CON131931(accessed 2December2014)."},{"key":"e_1_2_8_37_1","unstructured":"Reuters. FDA rejects Indivior's nasal spray for opioid overdose.2015. Available at:http:\/\/www.reuters.com\/article\/us-indivior-fda\u2010idUSKBN0TD2CS20151124#4mEOzP1TBZT2ABgY.97."},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2013.781565"},{"key":"e_1_2_8_39_1","unstructured":"HertzS.Naloxone for Outpatient Use: Data Required to Support an NDA. Silver Spring MD;2012. Available at:http:\/\/www.fda.gov\/downloads\/Drugs\/NewsEvents\/UCM300874.pdf(30 May 2014)."},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12360"},{"key":"e_1_2_8_41_1","volume-title":"American Association of Pharmaceutical Scientists","author":"Ehrick J.","year":"2013"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fadd.13209","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fadd.13209","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.13209","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.13209","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.13209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T13:55:55Z","timestamp":1694267755000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.13209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,3]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/add.13209"],"URL":"https:\/\/doi.org\/10.1111\/add.13209","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,3]]},"assertion":[{"value":"2015-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}